NCT06854536

Brief Summary

Microorganisms maintain a complex interrelationship with the human body, influencing each other. In recent years, people have gradually realized that the formation of the pediatric microecosystem is closely related to the development of gastrointestinal and even systemic immunity in children. The establishment of the pediatric microecosystem during childhood has significant implications for various diseases in adulthood. They are crucial for the host's nutrition, metabolism, resistance to pathogens, and immune function. Increasing evidence supports the association between gut microbiota abnormalities and the pathophysiology of food allergies, but the conclusions of existing clinical efficacy studies remain controversial. Previous research by the team has found that the gut microbiome has a clear impact on the occurrence and development of digestive and allergic diseases in children.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
17mo left

Started Feb 2025

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress56%
Feb 2025Feb 2028

Study Start

First participant enrolled

February 1, 2025

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

February 8, 2025

Completed
23 days until next milestone

First Posted

Study publicly available on registry

March 3, 2025

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2028

Last Updated

March 3, 2025

Status Verified

February 1, 2025

Enrollment Period

3 years

First QC Date

February 8, 2025

Last Update Submit

February 26, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Intestinal microbiome analysis

    The fecal samples from all participants will be collected and subjected to high-throughput metagenomic sequencing in order to elucidate the characteristics and composition of the intestinal microbiome in children with food allergies.

    The time point of confirming food allergy and the age of 36 months

  • Intestinal microbiome metabolites analysis

    This will be detected and analyzed by liquid chromatography-mass spectrometry (LC-MS) non-targeted metabolomics to analyze the metabolites of the intestinal microbiome.

    The time point of confirming food allergy and the age of 36 months

Secondary Outcomes (4)

  • Differences in clinical symptoms

    36 months of age

  • The percentile number of height of children at different groups

    The time point of confirming food allergy and the age of 36 months

  • The percentile number of head circumference of children at different group

    The time point of confirming food allergy and the age of 36 months

  • The percentile number of weight of children at different groups

    The time point of confirming food allergy and the age of 36 months

Study Arms (1)

Food-allergic children

Children diagnosed with food allergies

Eligibility Criteria

Age1 Month - 36 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Diagnosed with food allergy children aged 1-36 months old

You may qualify if:

  • Children aged 1-36 months old
  • Both men and women;
  • The child's legal guardian signed the informed consent to participate in the study.
  • The legal guardian of the child commits to follow the study procedures and cooperate with the entire study process

You may not qualify if:

  • Probiotics or antibiotics within 1 month
  • Associated with clinically significant abnormalities in liver and kidney function, nervous system, respiratory system, and coagulation function as determined by the investigator
  • Unstable vital signs;
  • Have other underlying medical conditions
  • Individuals deemed unsuitable for this clinical trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

faeces

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
36 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 8, 2025

First Posted

March 3, 2025

Study Start

February 1, 2025

Primary Completion (Estimated)

February 1, 2028

Study Completion (Estimated)

February 1, 2028

Last Updated

March 3, 2025

Record last verified: 2025-02

Locations